A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Phase of Trial: Phase II/III
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine
- Focus Therapeutic Use
- Sponsors Biohaven Pharmaceutical
- 21 Nov 2018 Planned primary completion date changed from 15 Feb 2020 to 30 Sep 2019.
- 15 Nov 2018 According to a Biohaven Pharmaceutical media release, first patient has been enrolled in this study. Top-line result from this study is expected in 2019.
- 15 Nov 2018 Status changed from not yet recruiting to recruiting.